Doripenem is a new affiliate of the carbapenem chic of beta-lactam antibiotics with broad-spectrum advantage of Gram-positive, Gram-negative and anaerobic bacilli agnate to imipenem and, especially, meropenem. This parenteral antibacterial may action hardly added action than meropenem adjoin called pathogens, including advantage of some strains of Pseudomonas aeruginosa strains not affected to the added antipseudomonal carbapenems. Empiric analysis with doripenem, as with added antipseudomonal carbapenems, may be advantageous in hospital and accelerated affliction assemblage settings area multidrug attrition has emerged, abnormally in Gram-negative enteric pathogens. When P. aeruginosa or multidrug-resistant Gram-positive bacilli such as methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci are involved, doripenem have to be acclimated in combination. Doripenem has a ample spectrum of action adjoin abounding accepted hospital pathogens, including P. aeruginosa and Burkholderia cepacia, which is agnate to meropenem.
Doripenem is acclimated to amusement astringent infections of the stomach, bladder, or kidneys.
Doripenem may aswell be acclimated for added purposes not listed in this medication guide.